[go: up one dir, main page]

MX2022001027A - Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo. - Google Patents

Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo.

Info

Publication number
MX2022001027A
MX2022001027A MX2022001027A MX2022001027A MX2022001027A MX 2022001027 A MX2022001027 A MX 2022001027A MX 2022001027 A MX2022001027 A MX 2022001027A MX 2022001027 A MX2022001027 A MX 2022001027A MX 2022001027 A MX2022001027 A MX 2022001027A
Authority
MX
Mexico
Prior art keywords
egfr
antibody
biaspecific
treating
pharmaceutical composition
Prior art date
Application number
MX2022001027A
Other languages
English (en)
Inventor
Na Rae Lee
Moo Young Song
Eunsil Sung
Jaehyun Eom
Yeunju Kim
Youngdon Pak
Young Bong Park
Yangsoon Lee
Hyejin Chung
Minji Park
Hyoju Choi
Yeryoung Yong
Ui-Jung Jung
Kyeongsu Park
Wonjun Son
Youngkwang Kim
Eun-Jung Lee
Eun Jung Lee
Original Assignee
Abl Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abl Bio Inc filed Critical Abl Bio Inc
Publication of MX2022001027A publication Critical patent/MX2022001027A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan un anticuerpo biespecífico anti-4-1BB/anti-EGFR, y una composición farmacéutica y un método para tratar y/o prevenir un cáncer usando la misma.
MX2022001027A 2019-07-26 2020-07-27 Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo. MX2022001027A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962878977P 2019-07-26 2019-07-26
PCT/KR2020/009870 WO2021020845A1 (en) 2019-07-26 2020-07-27 Anti-egfr/anti-4-1bb bispecific antibody and use thereof

Publications (1)

Publication Number Publication Date
MX2022001027A true MX2022001027A (es) 2022-04-18

Family

ID=74189704

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001027A MX2022001027A (es) 2019-07-26 2020-07-27 Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo.

Country Status (11)

Country Link
US (2) US12168690B2 (es)
EP (1) EP4004053A4 (es)
JP (2) JP7738545B2 (es)
KR (1) KR20220038767A (es)
CN (2) CN118221825A (es)
AU (1) AU2020320349A1 (es)
BR (1) BR112022001329A2 (es)
CA (1) CA3147420A1 (es)
MX (1) MX2022001027A (es)
WO (1) WO2021020845A1 (es)
ZA (1) ZA202200905B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118369340A (zh) * 2021-11-25 2024-07-19 盛禾(中国)生物制药有限公司 一种双特异性抗原结合蛋白
JP2025512915A (ja) * 2022-04-07 2025-04-22 ユハン コーポレーション Ｈｅｒ２の発現レベルが低いがんを治療又は予防するための薬学的組成物
KR20240164748A (ko) * 2023-05-12 2024-11-20 앱클론(주) 항체 또는 그의 항원 결합 단편, 및 어피바디를 포함하는 이중 항원 표적 단백질 복합체

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2185770T3 (es) * 1995-04-08 2003-05-01 Lg Chemical Ltd Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce.
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
RU2488597C2 (ru) 2005-02-07 2013-07-27 Гликарт Биотехнологи Аг Антигенсвязывающие молекулы, которые связывают egfr, кодирующие их векторы и их применение
AU2007294122B2 (en) * 2006-09-10 2013-03-07 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
ES2724801T3 (es) 2011-04-19 2019-09-16 Pfizer Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer
CN105899503B (zh) * 2013-08-16 2020-08-18 纪念斯隆-凯特琳癌症中心 选择性grp94抑制剂和其用途
SMT202400477T1 (it) * 2014-12-22 2025-01-14 Systimmune Inc Anticorpi tetravalenti bispecifici e loro procedimenti di fabbricazione e d'uso
JP7058213B2 (ja) * 2015-09-30 2022-04-21 アイジーエム バイオサイエンシズ インコーポレイテッド 改変ｊ鎖を有する結合分子
JP2019513373A (ja) 2016-03-31 2019-05-30 ネオン セラピューティクス， インコーポレイテッド ネオ抗原およびその使用方法
RU2018139339A (ru) * 2016-04-22 2020-05-22 Эллигейтор Биосайенс Аб Новые биспецифические полипептиды против cd137
SG11201908813QA (en) * 2017-04-13 2019-10-30 Aduro Biotech Holdings Europe B V Anti-sirp alpha antibodies
IL272103B2 (en) * 2017-07-20 2024-10-01 Aptevo Res & Development Llc Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods of treating cancer
CA3086653A1 (en) * 2017-12-28 2019-07-04 Julius-Maximilians-Universitat Wurzburg Tumor necrosis factor (tnf) receptor superfamily (tnfrsf) receptor-activating antibody fusion proteins with fcyr-independent agonistic activity (tnfrsf receptor-activating antibody fusion proteins with fcyr-independ ent agonistic activity; traaffiaa)
EP3880247A4 (en) * 2018-11-13 2022-10-26 JN Biosciences, LLC Bispecific antibodies for activation of immune cells
AU2019390274A1 (en) 2018-11-30 2021-07-22 Abl Bio Inc. Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof
MY207446A (en) * 2019-08-12 2025-02-27 Abl Bio Inc Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof
KR20220148228A (ko) * 2020-02-28 2022-11-04 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물, 다중 특이적 항체 및 그 용도

Also Published As

Publication number Publication date
ZA202200905B (en) 2023-11-29
US12168690B2 (en) 2024-12-17
WO2021020845A1 (en) 2021-02-04
AU2020320349A1 (en) 2022-02-17
BR112022001329A2 (pt) 2022-03-22
EP4004053A1 (en) 2022-06-01
JP2022542670A (ja) 2022-10-06
CN114450306B (zh) 2024-04-05
CN118221825A (zh) 2024-06-21
JP7738545B2 (ja) 2025-09-12
US20250066487A1 (en) 2025-02-27
KR20220038767A (ko) 2022-03-29
US20210024638A1 (en) 2021-01-28
CN114450306A (zh) 2022-05-06
JP2026004296A (ja) 2026-01-14
CA3147420A1 (en) 2021-02-04
EP4004053A4 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
MX2022001022A (es) Anticuerpo biespecifico anti-her2/anti-4-1bb y uso del mismo.
CO2022005077A2 (es) Compuestos moduladores de glp-1r
CL2021000458A1 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr (divisional de solicitud 201602359)
ZA202206885B (en) Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof
MX2019013858A (es) Inhibidores de kras g12c y metodos para su uso.
UY38353A (es) Inhibición de integrina alfavbeta6
MX2020008977A (es) Formulaciones de anticuerpos de her2 subcutaneas.
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
IL285923A (en) Compositions, methods, and kits for delivery of polyribonucleotides
PH12022550646A1 (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
CL2016002667A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
ZA202211405B (en) Anti-cd73-anti-pd-1 bispecific antibody and use thereof
BR112015032718A2 (pt) composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
EP4039705A4 (en) ANTIBODY DIRECTED TO BCMA, BISPECIFIC ANTIBODY AND USE THEREOF
MX2024012294A (es) RECEPTORES DE TGF-ß Y MÉTODOS DE USO
BR112022008558A2 (pt) Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso
MX2022001027A (es) Anticuerpo biespecifico anti-egfr/anti-4-1bb y uso del mismo.
WO2018009507A8 (en) COMBINATION OF A TIM -4 ANTAGONIST AND METHODS OF USE
MX2024002261A (es) Molecula de union de fap/cd40 y uso medicinal de la misma.
ZA202309150B (en) Antibody against nkp46 and application of antibody
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
PH12020552159A1 (en) Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
CL2020001856A1 (es) Métodos para tratar la enfermedad de farber.